Crohn's Disease and Current Treatment Challenges
Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by persistent inflammation of the digestive tract, leading to symptoms such as recurrent abdominal pain, diarrhea, and weight loss. The disease is marked by recurring cycles of remission (symptom alleviation) and active periods (symptom exacerbation), and is fundamentally challenging to cure.
Current treatment methods primarily focus on inflammation control through medication and surgical intervention when necessary. However, each approach presents its own challenges.
Challenges of Drug Therapy
Steroids, immunomodulatory drugs, and biological agents (such as anti-TNF antibodies) are commonly employed to suppress inflammation. While these medications can alleviate symptoms and induce remission in many cases, long-term use leads to adverse effects (such as an increased risk of infection and osteoporosis), and drug responsiveness gradually diminishes, resulting in reduced efficacy.
Moreover, while the medication alleviates symptoms, it does not provide a cure for the disease itself, leading to a continued risk of recurrence.
Challenges in Surgical Therapy
When complications such as severe intestinal strictures or fistulas (abnormal passages often characterized by pus formation) arise, surgical intervention is undertaken to resect the affected area or close the fistula. Although surgery can provide temporary symptomatic relief, it places a substantial burden on the body, and there is a significant likelihood of disease recurrence. Given that Crohn's disease can manifest in any segment of the gastrointestinal tract, inflammation may subsequently develop in other areas following surgery.
As long as the underlying cause remains unaddressed, lifelong treatment is necessary. Consequently, current medical approaches primarily focus on symptomatic therapy, aimed at suppressing symptoms, which presents limitations in achieving a complete cure. Both patients and their families must contend with concerns about side effects and the fear of recurrence, and many harbor the worry, "Will this continue indefinitely?"
In recent years, stem cell therapy and other regenerative medicine approaches have garnered attention as novel therapeutic options.
New Possibilities in Stem Cell Therapy and Regenerative Medicine for Crohn's Disease
Regenerative medicine is a medical field that harnesses the body's natural repair and regeneration capabilities to treat diseases. Central to this are cells called stem cells.
Stem cells are progenitor cells for various cell types in the body and possess the ability to repair damaged tissues and regenerate bodily functions. Among these, a type of stem cell known as mesenchymal stem cells (MSCs) exhibits immunomodulatory and tissue repair properties, and for inflammatory diseases such as Crohn's disease...
Currently, stem cell therapy is opening new possibilities for Crohn's disease. If traditional drug therapy is an approach of "aggressively suppressing the immune system's dysregulated inflammatory response with medication," then stem cell therapy, in other words, is an approach of "harnessing the body's natural reparative and regulatory functions."
The administration of stem cells, either autologous (from the patient's own body) or allogeneic (from a donor), via infusion and other delivery methods, is expected to modulate excessive inflammation and promote the regeneration of damaged tissue. In essence, this treatment aims to attenuate the dysregulated immune response characteristic of Crohn's disease and facilitate the healing of the intestinal mucosa.
Stem cells come in various types, and mesenchymal stem cells (MSCs) can be harvested from diverse tissues such as bone marrow, adipose tissue, and the umbilical cord. Of particular interest recently are Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs), which are stem cells isolated from the gelatinous tissue known as Wharton's jelly within the umbilical cord.
These WJ-MSCs offer the advantage that, as they are derived from umbilical cords discarded after birth, their extraction is painless and non-invasive. The obtained cells are also youthful, exhibiting enhanced proliferative capacity, and are immunologically less prone to rejection due to their inherent immune privilege and low immunogenicity.
Given these characteristics, WJ-MSCs are anticipated as a novel cell source in regenerative medicine and are beginning to be applied in stem cell therapy for Crohn's disease.
Mechanism of Action of Stem Cell Therapy for Crohn's Disease
How exactly do stem cells function upon entering the body? To facilitate a clearer understanding, let us explain this by drawing an analogy to a car's braking system and a repair facility.
In Crohn's disease, the immune system, which is intended to protect the body, dysfunctions and attacks its own intestines, leading to inflammation. This state is comparable to a car operating with faulty brakes.
Typically, the immune system possesses an 'accelerator role' that drives inflammation and a 'brake role' that suppresses it. In Crohn's disease, however, the 'brake' mechanism is dysfunctional, allowing the 'accelerator' to operate unchecked.
Here, stem cells act as a "braking mechanism" within the body, halting debilitating immune responses. Stem cells (specifically MSCs) release immunomodulatory signals in their vicinity, gently attenuating an uncontrolled immune response. This is comparable to installing new brakes on an erratically operating vehicle to reduce its velocity.
Furthermore, concerning compromised intestinal mucosa resulting from leakage, stem cells also function as reparative agents. MSCs accumulate at the damaged tissue and secrete factors that facilitate tissue repair.
This collection of substances is referred to as the secretome, encompassing various reparative agents, including inflammation-modulating cytokines and growth factors. This creates an environment where intestinal tissue damaged by inflammation can be more readily regenerated.
Furthermore, MSCs themselves have the capacity to differentiate into intestinal tissue cells as needed, and may directly support healing at the site of damage.
Secara ilmiah, sedikit suplemen:MSCs act as a command center that regulates the balance of immune cells. For example, it is reported that they enhance anti-inflammatory macrophages (M2 macrophages) and suppress the overactivity of cells like neutrophils and dendritic cells that trigger inflammation. Furthermore, they also act on T cells and B cells, which are key immune cells, reducing the release of inflammatory substances (cytokines) they produce to curb excessive immune responses. On the other hand, to promote the repair of damaged tissue, they also provide substances that generate new blood vessels and growth factors that aid tissue regeneration.
Through this complex mechanism, stem cell therapy is believed to achieve a dual effect: simultaneously mitigating inflammation and promoting tissue repair. In essence, stem cell therapy is a treatment modality that concurrently performs immunomodulatory functions and promotes tissue regeneration. By modulating the dysregulated immune system in Crohn's disease and facilitating the repair of damaged intestinal tissue, it is anticipated to achieve sustained remission (a state characterized by the prolonged absence of symptoms) and mucosal healing, which has historically been difficult to attain.
Evidence of the Effectiveness of Stem Cell Therapy for Crohn's Disease
Results of Meta-Analysis (Analysis of Combined Multiple Experiments):
According to an analysis combining several clinical trials published in 2024, when stem cell therapy was administered to patients with difficult-to-treat Crohn's disease where conventional treatments were insufficiently effective, the remission rate (a condition where symptoms subside) was approximately twofold higher compared to conventional treatment alone. This analysis synthesized data from 12 randomized trials (totaling 632 participants), yielding results with high scientific confidence.
It is also noteworthy that, as detailed in the subsequent safety section, the incidence of serious adverse events was comparable to the control group, demonstrating that while efficacy was enhanced, safety remained uncompromised.
Specific Achievements in Clinical Trials
Numerous clinical trials have also been reported that have investigated stem cell therapy in Crohn's disease patients. For instance, in a randomized controlled trial conducted in China involving the infusion of umbilical cord-derived mesenchymal stem cells (WJ-MSC), a significant improvement in symptom scores and a reduction in the required steroid dosage were observed in the group receiving stem cells, leading to the conclusion that stem cell therapy can safely ameliorate the disease condition.
Additionally, other research has reported cases where intestinal endoscopic findings improved following stem cell therapy, with subsequent mucosal healing, and cases where intractable fistulas closed. Indeed, for difficult-to-treat perianal fistulas occurring around the anus due to Crohn's disease, local injection of stem cells...
This achievement directly contributes to the improvement of patient quality of life (QOL).
Sample Overseas Agreement
The effectiveness of stem cell therapy is progressively being integrated into medical practice. A representative example is its approval in Europe. In 2018, a stem cell preparation (trade name: Alofisel®, generic name: darvadstrocel) was approved in Europe as a treatment for complex perianal fistulas in Crohn's disease. This preparation involves allogeneic adipose-derived mesenchymal stem cells (MSCs) that are cultured and injected into the affected area. It is indicated for refractory fistula patients where existing treatments (such as anti-TNF agents) have been ineffective.
The European Medicines Agency (EMA) has approved the indication for Alofisel, specifying its use for complex perianal fistulas refractory to conventional therapy, and it is recognized as the world's first stem cell therapy medicine. This approval serves as evidence that the effectiveness of stem cell therapy is gaining scientific and clinical recognition.
This evidence supports the potential that stem cell therapy offers to patients with Crohn's disease. It is important to note, however, that many applications are currently in clinical trial stages and are restricted to specific cases, not representing a universal cure. Nevertheless, a significant body of evidence has accumulated, fostering considerable hope that it "may offer a pathway to cure conditions previously deemed untreatable."
Stem cell therapy is currently undergoing continuous research. In the future, the scope of its effectiveness, duration, and other factors will be further elucidated.
Safety and Adverse Effects of Stem Cell Therapy for Crohn's Disease
When evaluating novel therapies, patients' primary concerns revolve around safety and potential side effects. The currently reported safety profile for stem cell therapies is highly favorable.
Across national and international clinical research, as previously outlined, serious adverse events are virtually never reported. For example, the aforementioned 2024 meta-analysis found no significant difference in the incidence rate of serious adverse events (such as infection or cancer) between patients receiving stem cell therapy and those undergoing conventional treatment alone, concluding that safety concerns were not elevated.
Stem cell therapy fundamentally involves the use of cells derived either from the patient's own body (autologous) or from human donors (allogeneic). Consequently, it is posited that the risk of systemic adverse effects from chemical agents, such as gastrointestinal disturbances or hepatic damage, commonly observed in conventional pharmacotherapy, is reduced.
When cells are administered into the body via infusion or injection, transient fever, headache, or allergic reactions are rare, and are predominantly mild and temporary when they do occur. Furthermore, even when using allogeneic stem cells, Mesenchymal Stem Cells (MSCs) inherently possess immunoprivileged properties, making them less susceptible to immune recognition. Consequently, rejection reactions are unlikely, allowing for the safe use of allogeneic cells.
Specifically, cells such as WJ-MSCs, characterized by low immunogenicity, have been confirmed to be well-tolerated by patients even in allogeneic settings. Furthermore, clinical trials and post-marketing data for the European-approved MSC preparation Alofisel® have reported no major safety concerns. While long-term safety observation and research are ongoing, reports indicate that patients have experienced no serious complications over a multi-year timeframe.
Conversely, potent conventional medications such as steroids are associated with various long-term side effects, including infections and metabolic disorders. Consequently, if stem cell therapy can reduce or obviate the need for these drugs, the overall risk of adverse effects may be diminished.
Overall, stem cell therapy represents a treatment with an exceptional balance of both effectiveness and safety. Of course, no treatment is "absolutely safe"; however, to date, no serious adverse events unique to stem cell therapy have been reported. We have therefore reached a stage where we can confidently proceed to clinical application.
Participants in clinical trials also reported experiencing "no major discomfort from the treatment" and "only receiving an infusion with minimal physical burden." Compared to conventional surgery and other interventions, this approach can be characterized as a treatment that is notably less taxing on the body.
Conclusion
Stem cell therapy for Crohn's disease is a novel and emerging treatment option. Research and development are currently underway, and while it is not a universal cure, it holds significant promise, offering a beacon of hope for a condition that has historically been challenging to manage.
For patients who have not achieved satisfactory outcomes with conventional treatments and are seeking further options, stem cell therapy holds the potential to be a promising next therapeutic avenue. This therapy is progressively being adopted in specialized regenerative medicine facilities and select medical institutions. In Japan, it is also implemented as advanced medical treatment and within clinical research frameworks. At our institution, we evaluate its suitability and may propose it as an option, tailored to the patient's specific condition.
Should you be wondering, "Is this an option for me (or my family)?" or "I would like to learn more details," please do not hesitate to consult with us. As healthcare providers, we are committed to collaboratively identifying the best treatment options for our patients and empowering them to proceed with their care confidently.
We hope that stem cell therapy, as a new frontier, offers reassurance and hope to patients and their families struggling with debilitating symptoms. With current medical advancements, the path toward conquering Crohn's disease is gradually becoming clearer. We believe that in the future, stem cell therapy will advance further, and a day will come when many individuals can lead their daily lives unburdened by illness.
If you are concerned about managing Crohn's disease, please do not struggle alone. We encourage you to consult a specialized medical facility. We offer comprehensive support, leveraging the latest knowledge and technology, to help you restore your intestinal health and well-being.